NCT02546323

A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 543 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 45 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.

Detailed description

This study is a randomized, double-blind, placebo-controlled, multicenter parallel group study assessing the effects of rosuvastatin 20 mg treatment for 104 weeks on the change in intimamedia thickness (IMT) of the common carotid artery (CCA), carotid bulb, and internal carotid artery (ICA) in adult Chinese subjects with subclinical atherosclerosis.

Conditions

• Atherosclerosis

Interventions

Type	Name	Description
DRUG	Rosuvastatin	20mg tablets, orally once daily for the duration of the 104-week treatment period
DRUG	Placebo	Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.

Timeline

• Start date: 2015-09-17
• Primary completion: 2019-01-29
• Completion: 2019-01-29
• First posted: 2015-09-10
• Last updated: 2019-12-11
• Results posted: 2019-12-11

Locations

24 sites across 1 country: China